Karalezli Aylin, Kaderli Sema Tamer, Kaderli Ahmet, Kaya Cansu, Sul Sabahattin
Department of Ophthalmology, Mugla Sitki Kocman University School of Medicine, Mugla, Turkey.
Department of Ophthalmology, Mugla Sitki Kocman Education and Training Hospital, Mugla, Turkey.
Taiwan J Ophthalmol. 2023 May 23;14(3):387-393. doi: 10.4103/tjo.TJO-D-22-00177. eCollection 2024 Jul-Sep.
To compare the effect of intravitreal ranibizumab (IVR) or intravitreal dexamethasone implants (IVD) on the regression of hyperreflective dots (HRDs) in patients with branch retinal vein occlusion (BRVO).
Thirty-seven eyes with cystoid macular edema who received IVR or IVD and followed up for at least 12 months were included in this study. The patients were divided into three Groups according to intravitreal treatments. Group 1 consisted of 12 eyes who received only IVD, Group 2 consisted of 10 eyes who received only IVR, and Group 3 consisted of 15 eyes who received both IVD and IVR. The number of HRDs and best-corrected visual acuity (BCVA) were compared between the Groups through the follow-up time.
The mean number of HRDs in inner and outer retinal layers was significantly decreased in Group 1 and Group 3 (For Group 1; < 0.001, = 0.001, for Group 3; < 0.001, < 0.001). At the 1 year, the number of HRDs in inner and outer retinal layers was significantly lower in Group 1 and Group 3 than Group 2 (All < 0.05). The BCVA was higher in Group 3 than Group 2 at 1 year ( = 0.048).
The HRDs should be considered inflammatory markers in the follow-up of CME in BRVO.
比较玻璃体内注射雷珠单抗（IVR）或玻璃体内注射地塞米松植入物（IVD）对视网膜分支静脉阻塞（BRVO）患者高反射点（HRD）消退的影响。
本研究纳入了37例接受IVR或IVD治疗并随访至少12个月的黄斑囊样水肿患者。根据玻璃体内治疗方法将患者分为三组。第1组由12只仅接受IVD治疗的眼睛组成，第2组由10只仅接受IVR治疗的眼睛组成，第3组由15只同时接受IVD和IVR治疗的眼睛组成。通过随访时间比较各组之间的HRD数量和最佳矫正视力（BCVA）。
第1组和第3组视网膜内、外层HRD的平均数量显著减少（第1组；<0.001，=0.001，第3组；<0.001，<0.001）。在1年时，第1组和第3组视网膜内、外层的HRD数量显著低于第2组（均<0.05）。第3组在1年时的BCVA高于第2组（=0.048）。
在BRVO合并黄斑囊样水肿的随访中，HRD应被视为炎症标志物。
